November 22, 2026
WhatsApp Image 2026-01-05 at 13.28.16

Lenacapavir

Uganda’s National Drug Authority (NDA) has approved Lenacapavir, a long-acting HIV prevention medicine administered just twice a year, in a major boost to the country’s fight against HIV/AIDS.

The approval was granted on Monday after the NDA Board Commission cleared two products manufactured by U.S.-based pharmaceutical company Gilead Sciences: Lenacapavir 300mg film-coated tablets and Lenacapavir sodium 464mg solution for injection.

Confirming the decision, NDA spokesperson Abiaz Rwamwiri said the products had successfully undergone rigorous regulatory assessment.

“I can confirm that this morning, the Authority (Board Commission) sat and approved Lenacapavir Gilead 300mg film-coated tablet and Lenacapavir sodium 464mg solution for injection,” Rwamwiri said.
“We hope this adds to Uganda’s efforts to end HIV/AIDS by 2030. However, this is not treatment but another preventative measure.”

A high-impact but costly prevention option

Lenacapavir is a pre-exposure prophylaxis (PrEP) medicine designed to prevent HIV infection among people at high risk. Unlike daily oral PrEP, the injectable formulation is taken once every six months, a development health experts say could greatly improve adherence.

However, the injection is expected to cost about US$2,000 (approximately Shs 8 million) per dose, a price that may limit access unless government and development partners step in to subsidize its rollout.

Not a cure, no STI protection

Health authorities have emphasized that Lenacapavir does not cure HIV and does not protect against other sexually transmitted infections, making continued use of condoms and regular testing essential.

Toward ending AIDS by 2030

Uganda has committed to ending HIV/AIDS as a public health threat by 2030. The approval of Lenacapavir adds a powerful new tool to the country’s prevention arsenal, alongside condoms, oral PrEP, voluntary medical male circumcision, and community-based interventions.

The Ministry of Health and NDA are expected to issue further guidance on pricing, access, and integration of Lenacapavir into national HIV prevention programs in the coming months.

About The Author

Leave a Reply

Your email address will not be published. Required fields are marked *